LRMR
Larimar Therapeutics, Inc. [LRMR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LRMR Stock Summary
Top 10 Correlated ETFs
LRMR
Top 10 Correlated Stocks
LRMR
In the News
LRMR Financial details
Company Rating
-
Market Cap
444.05M
Income
-35.84M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
42
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-6.53
Forward P/E
-
PEG
1.7
P/S
-
P/B
2.2
P/C
-
P/FCF
-9.45
Quick Ratio
14.58
Current Ratio
15.02
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.82
EPS next Y
-
EPS next Q
-
EPS this Y
-36.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
42.86%
-
-
-
-
SMA20
-4.66%
SMA50
-48.1%
SMA100
-50.97%
Inst Own
-
Inst Trans
-
ROA
-30%
ROE
-31%
ROC
-0.39%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.18-13.68
52W High
-75.46%
52W Low
+59.5%
RSI
37.56
Rel Volume
0.82
Avg Volume
628.2K
Volume
512.44K
Perf Week
1.27%
Perf Month
-19.44%
Perf Quarter
-59.97%
Perf Half Y
-60.81%
-
-
-
-
Beta
0.739
-
-
Volatility
0.05%, 0.21%
Prev Close
-2.45%
Price
3.19
Change
-4.78%
Company Profile
- Volume Average 628.2K
- Market Capitalization 444.05M
- Employee 42
- CEO Dr. Carole S. Ben-Maimon M.D.
- Headquarters Bala Cynwyd,PA,US
- IPO Date 2014-06-19
-
Website
https://www.larimartx.com 
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
